Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows
Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy's developer, ImmunoGen, recently announced. The data come from an ongoing Phase 1b/2 trial. Mirvetuximab soravtansine is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer. It is an antibody-drug conjugate that targets FRα-positive cancer cells and kills them with a toxic compound known as DM4. FORWARD II, a Phase 1b/2 study (NCT02606305), is evaluating the safety and preliminary efficacy of mirvetuximab soravtansine in combination regimens in patients with FRα-positive advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube tumors. Patients are assigned to receive mirvetuximab in combination with one of four chemotherapies: Avastin, Paraplatin, Doxil (pegylated liposomal doxorubicin), or Keytruda (pembrolizumab). The first part of the study is a dose escalation phase that will determine the maximum tolerated dose for each combination regimen. That will be followed by an expansion study with the defined maximum dose to assess safety, tolerability, and preliminary efficiency. ImmunoGen
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *